New drug aims to relieve stubborn shoulder pain in failed-treatment patients
NCT ID NCT05569174
First seen Jan 03, 2026 · Last updated May 12, 2026 · Updated 20 times
Summary
This study tested whether secukinumab, an injected drug, can reduce pain and improve function in adults with moderate to severe rotator cuff tendinopathy (shoulder tendon injury) who did not improve with standard treatments. 62 participants received either secukinumab or a placebo over 24 weeks. The main goal was to measure changes in shoulder-related quality of life using a patient questionnaire.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENDINOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Karlsruhe, Baden-Wurttemberg, 76133, Germany
-
Novartis Investigative Site
Munich, Bavaria, 80809, Germany
-
Novartis Investigative Site
Hanover, Lower Saxony, 30159, Germany
-
Novartis Investigative Site
Halle, Saxony-Anhalt, 06120, Germany
-
Novartis Investigative Site
Bad Doberan, 18209, Germany
-
Novartis Investigative Site
Berlin, 10787, Germany
-
Novartis Investigative Site
Berlin, 12627, Germany
-
Novartis Investigative Site
Cottbus, 03042, Germany
-
Novartis Investigative Site
Dresden, 01069, Germany
-
Novartis Investigative Site
Erlangen, 91054, Germany
-
Novartis Investigative Site
Frankfurt am Main, 60313, Germany
-
Novartis Investigative Site
Gladbeck, 45968, Germany
-
Novartis Investigative Site
Hamburg, 20095, Germany
-
Novartis Investigative Site
Hamburg, 20149, Germany
-
Novartis Investigative Site
Hamburg, 22415, Germany
-
Novartis Investigative Site
Heinsberg, 52525, Germany
-
Novartis Investigative Site
Herne, 44649, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Schönebeck, 39218, Germany
Conditions
Explore the condition pages connected to this study.